|Bid||0.4040 x 800|
|Ask||0.4250 x 1800|
|Day's Range||0.3720 - 0.4400|
|52 Week Range||0.2500 - 1.8400|
|Beta (3Y Monthly)||1.91|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
Applied DNA Sciences Inc. (APDN) (“Applied DNA”, the “Company”), a leader in PCR-based DNA manufacturing for product authenticity and traceability solutions, announced today a sales and marketing partnership with Navarpluma that extends Applied DNA’s Textiles business to include the global down and feather supply chain1. Formalization of the partnership between the two companies follows the completion of a groundbreaking technological advance by Applied DNA to utilize its SigNature® DNA system to allow for traceability of materials in the down and feather industry. Navarpluma S.L., one of the world’s premier suppliers of down and feathers to the textile industry, will be the first to offer this new system to its customer base that counts some of the world’s most prestigious brands as clients.
LineaRx, Inc. (“LineaRx”), a majority-owned subsidiary of Applied DNA Sciences, Inc. (APDN) (“Applied DNA” or the “Company”) announced that, in a decision rendered on August 7, 2019, the Centers for Medicare and Medicaid Services (CMS) approved chimeric antigen receptor (CAR) T-cell therapies that fit the CMS criteria for Medicare beneficiaries nationwide. LineaRx believes its unique method of manufacturing DNA is well poised to benefit from the increasing demand for nucleic-acid dependent therapies, like CAR T, as biotechnology companies pursue their gene and cell therapies with reimbursement assured by the CMS decision. CAR T-based treatments involve extracting and genetically altering a patient’s T cells to attack a protein on the surface of cancer cells.
LineaRx, Inc. (“LineaRx”), a wholly-owned subsidiary of Applied DNA Sciences, Inc. (“Applied DNA or the Company,” NASDAQ:APDN), announced today that it has acquired the physical assets and Intellectual Property (IP) of Vitatex Inc. (“Vitatex”), a private biotechnology company focused on advancing personalized medicine with an innovative solution that isolates Invasive Circulating Tumor Cells (iCTCs) from standard patient blood samples. Vitatex’s solution identifies metastatic cells often before primary tumors are visible to other diagnostic technologies, when preventive care for impending cancer is still an option. “We are honored to now include Vitatex executives on our team and employ its powerful technology within our platform,” said Dr. James Hayward, president and CEO of LineaRx.
Applied DNA products and services offer forensic, high-value differentiation for Schreiner MediPharm’s customers to secure supply chains
Applied DNA Sciences, Inc. , announced today it plans to release financial results for its fiscal 2019 third quarter ended June 30, 2019 after market close on Tuesday, August 13, 2019.
Applied DNA Sciences Inc. (APDN) (“Applied DNA” or the “Company”), a leader in PCR-based (Polymerase Chain Reaction) DNA manufacturing for product authenticity and traceability solutions, today announced that the Company and TheraCann International Benchmark Corporation (“TheraCann”) have signed a non-binding term sheet (the “Term Sheet”) outlining agreed-upon amendments to the exclusive licensing and cooperation agreement signed March 28, 2019 between the parties (the “Agreement”). The Term Sheet is expected to be followed by definitive contractual amendments. Under the Term Sheet, the parties agreed to amend the Agreement to provide Applied DNA with $4M in TheraCann convertible preferred stock and a $1M convertible promissory note in exchange for Applied DNA’s waiver of $4M in cash payments due from TheraCann on or before August 15, 2019.
Every investor in Applied DNA Sciences, Inc. (NASDAQ:APDN) should be aware of the most powerful shareholder groups...
LineaRx, Inc. a wholly-owned subsidiary of Applied DNA Sciences, Inc. (APDN), announced today that it has shipped multiple customized linear DNA amplicons to Evotec SE, a well-known therapeutic development company, to support their research efforts related to neurodegenerative diseases such as Huntington’s, Parkinson’s or Alzheimer’s disease. “Evotec SE, like a growing number of other cutting-edge biotech companies, sees value in evaluating linear DNA as a foundation for their research and recognizes the strengths of LineaRx in the design and large-scale production of linear DNA using LineaRx’s proprietary platform for DNA production by polymerase chain reaction (“PCR”).
ETCH biotrace to Combine Applied DNA’s DNA tag-based Forensic Traceability and Authenticity with TruTrace's Industry Blockchain Hub to Deliver Unparalleled Tag-Test-Track Capabilit
Applied DNA Sciences, Inc. (APDN), announced today that its scientific paper entitled, ‘Rapid authentication of pharmaceuticals via DNA tagging and field detection’, has been published in the June 2019 edition of PLOS ONE, detailing a novel Physical-Chemical Identifier (PCID) to authenticate and track legitimate pharmaceutical products through the pharmaceutical supply chain.
Includes Implementation of TheraCann’s ETCH biotrace™ platform Utilizing Technology from Applied DNA
Applied DNA Sciences, Inc. (APDN) (“Applied DNA” or the “Company”), provides an update today on its accomplishments toward commercial-scale production to support global material traceability for companies declaring sustainability goals to be achieved by 2020. CertainT-verifiable products are now available through supply chain partners and brands, including Amazon and other e-commerce and retail stores, with outlook for growth as product flows to store shelves. The CertainT platform and forensic services were conceived to empower companies with the most advanced commercially-scalable and affordable technologies to help prove their compliance with stated sustainability goals.
Applied DNA Sciences, Inc. (“Applied DNA,” “the Company,” NASDAQ: APDN), today announced that it has closed the loop on traceability for Egyptian Pima using DNA-based genotyping assays for cotton authentication. The Egyptian Pima developments join and expand a series of US Pima cotton assays performed within Applied DNA testing services and are based on work conducted over the past 3 years related to the validation of a known library of cotton cultivar standards.
LineaRx, a wholly-owned subsidiary of Applied DNA Sciences, Inc. (APDN), announced that it is in process of designing new, custom amplicons for an existing customer in the in vitro diagnostics market. The diagnostic assay is expected to be available and qualified in 2020, potentially resulting in increasing revenue from an existing supply agreement. The company currently receives annual orders for large-scale DNA from this customer under a 5-year supply agreement executed in 2017.
Applied DNA Sciences, Inc. (APDN), announced today that partner TheraCann International Benchmark Corporation (“TheraCann”), a leading full service international cannabis consultancy and technology firm, in conjunction CannAcubed Pte Ltd (CannAcubed), a pioneer in the China cannabis space with a focus on building the world’s largest diversified cannabis operations, has formed an agreement focused on the implementation of TheraCann’s molecular-tagging ETCH biotrace™ technology for the industrial hemp and cannabinoid markets in China.
Applied DNA Sciences, Inc. (APDN), will hold its 2019 Annual Meeting of Stockholders on Thursday, May 16, 2019. On that date, the company will provide an audio-only live webcast of the meeting beginning at 10:00 AM ET. Slide presentations accompanying the webcast will be available for download at that time on the ‘Events and Presentations’ portion of the ‘Investors’ page to the company’s website.
The Stony Brook, New York-based company said it had a loss of 8 cents per share. The DNA-based security technology company posted revenue of $778,500 in the period. Its adjusted revenue was $778,000. In ...
Applied DNA Sciences, Inc. (APDN), announced today that American & Efird (A&E), a portfolio company of Elevate Textiles and the world’s foremost manufacturer and distributor of industrial and consumer sewing thread, embroidery thread and technical textiles, has announced it will be previewing its new line of advanced identification threads, branded “Integrity” later this month. A&E will publicly display this latest breakthrough at the upcoming Texprocess trade show in Frankfurt Germany.